Concordia International Corp. announced the election of Maurice Chagnaud to its board of directors, effective November 1, 2018. Mr. Chagnaud has more than 25 years of experience in the pharmaceutical sector including senior and leadership roles at Merck KgAa, Merck Generics, Teva, Lupin and Polpharma. Geographically, he has extensive experience working in France, Italy, Germany, Central and Eastern Europe, Russia and the Commonwealth of Independent States, where he managed the commercial activities of generic, OTC and speciality product portfolios. Going forward, Concordia intends to build upon its current capabilities and global footprint across more than 90 countries, with a particular focus on both organic and inorganic growth in Europe.